3-18-21 In close collaboration with various working groups the research team was now able to develop a hydrogel that boasts an ideal combination: it is not only electrically conductive, but also retains its original level of elasticity. For the conductivity, the scientists used graphene, a material that has already been used in other production approaches.
“Graphene has outstanding electrical and mechanical properties and is also very light,” says Dr Fabian Schütt, junior group leader in the Research Training Group, thus emphasising the advantages of the ultra-thin material, which consists of only one layer of carbon atoms. What makes this new method different is the amount of graphene used. “We are using significantly less graphene than previous studies, and as a result, the key properties of the hydrogel are retained,” says Schütt about the current study, which he initiated.
https://www.nanowerk.com/nanotechnology-news2/newsid=57553.php
………………………………………………..
2-27-20 Electrically Conducting Hydrogel Graphene Nanocomposite Biofibers for Biomedical Applications https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056842/
……………………………………………….
2021 Graphene Integrated Hydrogels Based Biomaterials in Photothermal Biomedicine https://www.mdpi.com/2079-4991/11/4/906/htm
……………………………………………
11-27-20 Mojtaba Hoseini-Ghahfarokhi, 1, 2 Soroush Mirkiani, 3 Naeimeh Mozaffari, 4 Mohamad Amin Abdolahi Sadatlu, 5 Amir Ghasemi, 6, 7 Somayeh Abbaspour, 6 Mohsen Akbarian, 8 Fatemeh Farjadian, 8 Mahdi Karimi 9
1Nano Drug Delivery Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Radiology and Nuclear Medicine Department, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran; 3Neuroscience and Mental Health Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; 4Research School of Electrical, Energy and Materials Engineering, The Australian National University, Canberra 2601, Australia; 5Department of Engineering and Science, Sharif University of Technology-International Campus, Kish, Iran; 6Department of Engineering, Durham University, Durham DH1 3LE, United Kingdom; 7Advanced Nanobiotechnology and Nanomedicine Research Group (ANNRG), Iran University of Medical Sciences, Tehran, Iran; 8Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; 9Iran Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
Since graphene discovery in 2004, extensive studies have been done for understanding its physical and chemical properties. Owing to its unique characteristics, it has rapidly became a potential candidate for nano-bio researchers to explore its usage in biomedical applications. In the last decade, remarkable efforts have been devoted to investigating the biomedical utilization of graphene and graphene-based materials, especially in smart drug and gene delivery as well as cancer therapy. Inspired by a great number of successful graphene-based materials integrations into the biomedical area, here we summarize the most recent developments made about graphene applications in biomedicine. In this paper, we review the up-to-date advances of graphene-based materials in drug delivery applications, specifically targeted drug/ gene delivery, delivery of antitumor drugs, controlled and stimuli-responsive drug release….https://www.dovepress.com/applications-of-graphene-and-graphene-oxide-in-smart-druggene-delivery-peer-reviewed-fulltext-article-IJN
…………………………………………………………
1-15-2014 On-demand release of drug molecules from biomedical devices enables precise, targeted dosing that can be temporally tuned to meet requirements for a variety of therapeutic applications.(1-3) Recent advances have facilitated the use of various cues, such as UV- and visible-wavelength light, NIR radiation, magnetic field, ultrasound and electrical stimulation to trigger drug release in vivo from implanted smart materials.(1, 4, 5) These techniques enable greater control over drug delivery, compared to traditional in vivo drug-release systems that rely on passive delivery that is programmed prior to implantation and cannot be modified in response to changing therapeutic needs. To achieve precise, controlled drug delivery, nanomaterial drug carriers are increasingly investigated because of their unique structures and tunable properties.(6, 7) For example, the large surface area and sp2 carbon lattice associated with carbon nanomaterials, such as carbon nanotubes, graphene, and graphene oxide (GO), enable highly efficient drug loading, while their capacity for modification provides multiple routes for targeted and controlled drug delivery.(8, 9)
https://pubs.acs.org/doi/10.1021/nn406223e
………………………............................…
Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice 10-6-20
Qiuzhen Liang1 ,* Haibin Xiang1 ,* Xinyu Li,2 Chunxia Luo,2 Xuehong Ma,2 Wenhui Zhao,2 Jiangtao Chen,1 Zheng Tian,1 Xinxia Li,2 Xinghua Song3,4
1Department of Orthopaedics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, People’s Republic of China; 2School of Pharmacy, Xinjiang Medical University, Urumqi 830011, People’s Republic of China; 3Department of Orthopaedic, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province 510630, People’s Republic of China; 4Department of Orthopaedic, The Affiliated Shunde Hospital of Jinan University, Foshan, Guangdong Province 528303, People’s Republic of China
In the present study, rifapentine (RPT)-loaded PLGA and PLGA–PEG NPs were prepared using premix membrane homogenisation combined with solvent evaporation method. RPT was chosen as a model drug for the following reasons: (i) Although rifampicin is the first-line anti-TB drug amongst rifamycin antibiotics, there were half a million new cases of rifampicin-resistant TB in 2018,1 which may limit its clinical application. RPT is a rifamycin derivative, and RPT-based combination therapy could prevent the emergence of rifampicin-resistant M. tuberculosis.16 (ii) Compared with rifampicin, RPT is several times more active against M. tuberculosis with MIC of 0.02–0.06 μg/mL,17 which is beneficial for reducing the dosage. (iii) Importantly, the major advantage of RPT is that it has a much longer half-life than rifampicin,18 which makes it an ideal rifamycin antibiotic for reducing the dosing frequency. However, RPT also suffers from some drawbacks such as poor water solubility, elevation in serum aminotransferase and clinically apparent acute liver injury.19,20 In addition, the fact that M. tuberculosis is an intra-macrophage pathogen limits the use of conventional RPT, and if they even reach the target site, they have inefficient intracellular penetration. Therefore, we encapsulated RPT into PLGA or PLGA–PEG NPs as PLGA-based nanostructures will offer a very suitable medium for enhancing the advantages whilst reducing the disadvantages of RPT described above. To the best of our knowledge, polymeric nano-formulations of RPT have not yet been reported in the literature, and this is the first study that investigated the effect of RPT-loaded PLGA-based NPs on their cellular uptake, antitubercular activity, pharmacokinetics and biodistribution after oral administration to mice. https://www.dovepress.com/development-of-rifapentine-loaded-plga-based-nanoparticles-in-vitro-ch-peer-reviewed-fulltext-article-IJN
…………………………………………………………
SINOPEG At present, the company has a variety of mRNA vaccine lipid excipients with independent intellectual property rights, and can be customized according to customer entrustment. Many of our products (including customized structures) have been verified by many mRNA vaccine manufacturers and have completed quality research data. https://www.sinopeg.com/covid-19-vaccine-excipients_c138
…………………………………………
No comments:
Post a Comment